Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology (NASDAQ: NAUT) will participate in the TD Cowen 46th Annual Health Care Conference.
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT) will participate in the TD Cowen 46th Annual Health Care Conference. Management is scheduled for a fireside chat on March 2, 2026 at 10:30 a.m. ET. A live and archived webcast will be available on the company Investors website at www.nautilus.bio.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NAUT
In the Feb 20 session, NAUT declined 2.42%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 46th annual
- TD Cowen Health Care Conference
- Presentation date
- March 2, 2026
- Fireside chat schedule
- Presentation time
- 10:30 a.m. Eastern Time
- TD Cowen fireside chat
Historical Context
-
Announced timing of Q4 and full-year 2025 results and webcast details.
-
MJFF-supported collaboration on Parkinson’s single-molecule proteomics assay.
-
Launched early access program focused on tau proteoforms assay for researchers.
-
Reported first external field evaluation unit with reproducible multi-site data.
-
Lower operating expenses, narrower loss, and strong cash balance disclosure.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference.
Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.